Top

Published in:

Open Access 01-12-2011 | Commentary

Ten years of progress in radiation oncology

Author: Dirk Vordermark

Published in: BMC Cancer | Issue 1/2011

Abstract

Over the last decade, BMC Cancer has continuously published important research from the field of radiation oncology. Major developments in this field include the introduction of new imaging modalities into radiotherapy planning, the availability of hardware and software for more precise delivery of radiation dose, the individualization of radiotherapy concepts, for example, based on microarray data, and the combination of radiotherapy with molecular targeting approaches to overcome the radioresistance of tumor cells.

Available only for authorised users

Meert AP, Paesmans M, Berghmans T, Martin B, Mascaux C, Vallot F, Verdebout JM, Lafitte JJ, Sculier JP: Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer. 2001, 1: 5-10.1186/1471-2407-1-5.CrossRefPubMedPubMedCentral

Thorwarth D, Eschmann SM, Scheiderbauer J, Paulsen F, Alber M: Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer. 2005, 5: 152-10.1186/1471-2407-5-152.CrossRefPubMedPubMedCentral

Kazi A, Godwin G, Simpson J, Sasso G: MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer. BMC Cancer. 2010, 10: 472-10.1186/1471-2407-10-472.CrossRefPubMedPubMedCentral

Vordermark D, Kölbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M: Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer. 2005, 5: 55-10.1186/1471-2407-5-55.CrossRefPubMedPubMedCentral

Combs SE, Behnisch W, Kulozik AE, Huber PE, Debus J, Schulz-Ertner D: Intensity Modulated Radiotherapy (IMRT) and Fractionated Stereotactic Radiotherapy (FSRT) for children with head-and-neck-rhabdomyosarcoma. BMC Cancer. 2007, 7: 177-10.1186/1471-2407-7-177.CrossRefPubMedPubMedCentral

Ganswindt U, Paulsen F, Corvin S, Eichhorn K, Glocker S, Hundt I, Birkner M, Alber M, Anastasiadis A, Stenzl A, Bares R, Budach W, Bamberg M, Belka C: Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition. BMC Cancer. 2005, 5: 91-10.1186/1471-2407-5-91.CrossRefPubMedPubMedCentral

Hsieh CH, Kuo YS, Liao LJ, Hu KY, Lin SC, Wu LJ, Lin YC, Chen YJ, Wang LY, Hsieh YP, Lin SL, Chen CY, Chen CA, Shueng PW: Image-guided intensity modulated radiotherapy with helical tomotherapy for postoperative treatment of high-risk oral cavity cancer. BMC Cancer. 2011, 11: 37-10.1186/1471-2407-11-37.CrossRefPubMedPubMedCentral

Nikoghosyan AV, Karapanagiotou-Schenkel I, Münter MW, Jensen AD, Combs SE, Debus J: Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study. BMC Cancer. 2010, 10: 607-10.1186/1471-2407-10-607.CrossRefPubMedPubMedCentral

Rajkumar T, Vijayalakshmi N, Sabitha K, Shirley S, Selvaluxmy G, Bose MV, Nambaru L: A 7 gene expression score predicts for radiation response in cancer cervix. BMC Cancer. 2009, 9: 365-10.1186/1471-2407-9-365.CrossRefPubMedPubMedCentral

10.

Azria D, Bibeau F, Barbier N, Zouhair A, Lemanski C, Rouanet P, Ychou M, Senesse P, Ozsahin M, Pèlegrin A, Dubois JB, Thèzenas S: Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer. BMC Cancer. 2005, 5: 62-10.1186/1471-2407-5-62.CrossRefPubMedPubMedCentral

11.

Lee CM, Tannock IF: The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer. 2010, 10: 255-10.1186/1471-2407-10-255.CrossRefPubMedPubMedCentral

12.

Kessler J, Hahnel A, Wichmann H, Rot S, Kappler M, Bache M, Vordermark D: HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer. 2010, 10: 605-10.1186/1471-2407-10-605.CrossRefPubMedPubMedCentral

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/503/prepub

Title: Ten years of progress in radiation oncology
Author: Dirk Vordermark
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-11-503

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma

Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy

The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation

Paraneoplastic syndrome mimicking adult-onset Still's disease caused by advanced lung cancer: a case report

A multilevel investigation of inequalities in clinical and psychosocial outcomes for women after breast cancer

Breast cancer and human papillomavirus infection: No evidence of HPV etiology of breast cancer in Indian women

Keynote webinar | Spotlight on antibody–drug conjugates in cancer